LSIPR 50 2018: Leading the transformation change


LSIPR 50 2018: Leading the transformation change

Scott Alban of AstraZeneca outlines the company’s recent transformation aimed at breaking down barriers and the uncharted territories that it is eager to explore.

Charged with protecting the innovation arising from MedImmune, the global biologics research and development arm of AstraZeneca, as well as AstraZeneca’s innovative medicines and early development biotech units, Scott Alban’s job is far from insignificant.

Alban was behind AstraZeneca and MedImmune’s recent transformation of its global IP organisation to circumvent geographic and cultural barriers between the IP professionals who support pharmaceuticals and biologics across seven global sites.

“We wanted to empower our attorneys and other patent professionals to work collaboratively across multiple therapy areas, technology platforms and therapeutic modalities,” he says.

Scott Alban, LSIPR 50 2018, AstraZeneca, MedImmune, biology, research and development, innovation, biotech